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ABSTRACT
Quantitative Real Time PCR  has started to be used to quantitatively analyze mRNA expression
levels. In muscle overload in rats, interleukin-6 mRNA levels is thought to increase a significant
amount, while b-actin should remain constant.   IL-6 is thought to activate the Jak/STAT
pathway to induce muscle hypertrophy.   An b-actin assay was optimized and is ready to be
implemented on test samples, but the IL-6 assay because of primer problems was not completed.
The problem lied in the fact that very few assays have been developed to effectively receive
results.
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INTRODUCTION
Muscle research has been conducted for years to identify mechanism controls for muscle atrophy
and hypertrophy.  Muscle hypertrophy is the division of myoblasts, which fuse to the already
present muscle fibers to increase muscle mass, increase protein synthesis, and decrease muscle
degradation.  Most of this research has focused on cardiac muscle, because heart disease is a
common Western world problem and resulted in major funding from corporations for the cardiac
muscle research.  Researchers have started to investigate skeletal muscle more in-depth.  Skeletal
muscle atrophy has been identified in many diseases and health problems such as cancer,
Acquired Immune Defiency Syndrome (AIDS), and arthritis.  The elderly population of the
world has grown in the last decade, increasing the problem of muscle atrophy.  The muscle mass
of elderly decrease as their age increases.  With an already decreased muscle mass, falls due to
muscle weakness are debilitating or fatal to the elderly.  Also, Booth and Criswell (1997), stated
that space astronauts experienced muscle atrophy because of the weightlessness environment.
Their muscle atrophy endangers their lives because most emergency procedures require maximal
muscle strength making these procedures fatal due to the weakened muscles of the astronauts.
This study looked at interleukin-6 (IL-6), a cytokine, and its possible role of activating the Janus
kinase (JAK)/Signal Transducers and Activators of Transcription (STAT) pathway to induce
muscle hypertrophy.  Understanding the molecular controls of hypertrophy is necessary to
combat muscle atrophy, which is the ultimate goal of this study.
The Jak/STAT pathway is a very important molecular signaling pathway
involving many different factors to activate the pathway.  Cytokines for the
purpose of the present study start the pathway.   IL-6 as seen in Fig 1.,
specifically binds to the interleukin-6 receptor, also know as glycoprotein 80
(gp80).  Then gp130s (transmembrane receptors) are recruited to
homodimerize to the IL-6.  Janus Kinases then bind to the dimerized gp130.
Figure 1. Il-6 activation of
               Jak/STAT pathway
               Imada K. &
               Leonard W.J.
               (2000)Seehafer  et. al.  2001    3
A Schematic representation of JAK/STAT pathway can be seen in Fig. 2.  An IL-6
related cytokine binds to its transmembrane receptors.  This cytokine is constitutively associated
with Jaks.  The Jaks phosphorylated the tyrosine on the receptors.  STAT molecules bind to the
phosphorylated tyrosine and are activated. The activated STATs move away from the Jaks and
bind to each other via the SH2 domain attaching to the phosphate on the tyrosine of the other
STAT molecule.  Once two STATs are connected they translocate to nucleus and start
transcription. The Jak/STAT pathway is then activated.
Cardiac muscle studies aided in the identification of the role IL-6 and the Jak/STAT pathway’s
possible role in muscle hypertrophy.  A study conducted by Pan et. al. (1998) showed that the
increased mRNA of IL-6 in a pressure overload rat heart played a role in cardiac hypertrophy.  In
this study, IL-6 was shown to be an activator of the Jak/STAT pathway via gp130 because the
mRNA of IL-6 was elevated 2-fold in pressure overloaded rats compared to the sham operated
rats.  Kunisada et. al. (2000) presented research at a conference for the American Heart
Association that suggested that IL-6 or an IL-6 related cytokine activated gp130 initiated the
Jak/STAT pathway to induce hypertrophy in cardiac myocytes.  These studies indicate a role for
IL-6 and the Jak/STAT pathway in cardiac and skeletal muscle hypertrophy.
In 1998, Ostrowksi et. al.  showed that IL-6 increased in human skeletal muscles after prolonged
exercise.  This study hypothesized that IL-6 was produced in skeletal muscle as a reaction to
inflammation from extensive exercise.  Ostrowski and his group collected blood samples and
muscle biopsies from runners one week before, directly after, and two hours after the
Copenhagen Marathon to analyze the IL-6 concentration in the plasma and amount of IL-6
mRNA in muscle tissue.  The results showed that plasma levels of IL-6 peaked after exercise, but
remained present two hours after the marathon.  Before exercise, IL-6 was very minimal in the
plasma.  The mRNA of IL-6 was increased in the muscle biopsies after exercise and a few
Figure 2. Schematic representation of JAK/STAT pathway. 1) Cytokine binding to associated receptors.  2) JAK activation through phosphorylation of Tyrosine residues.
3) Associated receptors are phosphorylated by the activated JAKs.  4) Latent STAT proteins are recruited to the receptors and are activated by phosphorylation.  5)
STATs homo- or hetero-dimerize forming the Sis inducing factor (SIF) complex and translocate to the nucleus.  6) SIF binds to Sis Inducing Element (SIE) site in the
DNA and activates transcription.
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samples had IL-6 present after the two hour break.  Again, little to no mRNA of IL-6 was present
in the muscle prior to exercise.  In the blood samples, no IL-6 was found in any of the circulating
blood cells during any of the time points.  Similarly, Steensberg et. al. (2000) also showed that
IL-6 produced by skeletal muscle. This research has reaffirmed that IL-6 is produced in the
skeletal muscles and not in blood cells.
Jonsdottir et. al. (2000) conducted an experiment on rat skeletal muscles that hypothesized that
IL-6 production is in response to skeletal muscle contractions, but might reflect the type of
muscle contractions performed and the degree of muscle damage each type caused.   The rat’s
muscle was electrically stimulated to perform both eccentric and concentric contraction.  This
group used both types to see if IL-6 mRNA was produced only when muscle damage occurred or
if it is also produced during regular exercise.  The levels of mRNA levels of IL-6 in eccentric
and concentric both increased, but eccentric contractions caused more IL-6 mRNA production
than concentric.  These results show that that IL-6 mRNA production is not just a response to
muscle inflammation and damage, but also to normal exercise.  However, more IL-6 mRNA was
produced when muscle damaged occurred during eccentric contractions, which sugguested that
IL-6 mRNA increase was caused by both muscle work and an immune response to muscle
damage.
Tsujinaka et. al. (1996) used transgenic IL-6 mice to test IL-6 chronic overexpression.  It proved
that if IL-6 was expressed in a high level for an extend period of time that IL-6 caused muscle
degradation.  When the mice were injected with antibody IL-6R to block the signal led to the
mice did not lose muscle mass.  This study suggested that in overexpression of IL-6 for an
extend length of time, the IL-6 used another pathway other than Jak/STAT to cause muscle
protein turnover.
In 2001, Carson and Reecy induced functional overload of the soleus muscle with Sprague-
Dawley rats.  Carson of the University of South Carolina, Medical Branch, cut out one-third of
gastrocnemius muscle out of mature rats to induce the muscle overload of the soleus muscle out
of half the rats in an assay from Baldwin et. al. (1982). The other half received a sham operation
to act as a control.  The sham operation consisted of the same procedure as the overload rats,
except for the gastronemius removal process.  RNA samples were collected from the soleus
muscle of the animals at 12 hours, one day, three days, seven days, and 21 days after muscle
overload was induced.  An Affymetrix rat U34A GeneChip was used for microarray analysis of
the 3 day time point.  From this microarray, overloaded animals were compared to Sham
operated animals.  IL-6 expression levels were seen to increase 15-fold in the overloaded animals
from the sham operated animals.
This study hypothesized that IL-6 mRNA would be elevated by a 5-fold or greater margin  from
3 days to 7 days of muscle overload compared to the sham animals.  Then the mRNA levels of
IL-6 would return to normal after this time point.  If the IL-6 mRNA levels stay elevated for that
length of time, it would sugguest that IL-6 does induce muscle hypertrophy via the Jak/STAT
pathway.
The present study, the RNA collected from Carson and Reecy was used.   The RNA was
analyzed by Real Time PCR to observe the duration of elevated IL-6 mRNA levels after the
functional muscle overload was induced.  The method used to detect the amount of mRNA wasSeehafer  et. al.  2001    5
Real Time Polymerase Chain Reaction(PCR) on a Cepheid Smart Cycler PCR System.  Real
Time PCR is a PCR process that measures the fluorescence of each sample at the end of each
sample.  This data was then quantified.  SYBR Green served as the fluorescent intriculating dye
to measure the amount of fluorescence of each sample.
METHODS AND MATERIALS
cDNA synthesis
The total RNA from Dr. James Carson was reverse transcribed into cDNA using two different
protocols. The first cDNA was synthesized using Gibco BRL Superscript II RT cDNA Synthesis
Kit from Life Technologies, Inc (Baltimore, MD).  A 1 mg of RNA of each sample was mixed
with 1ml random primers, 1ml of dNTP (10mM), and added up to 10ml with DEPC-treated H2O
and incubated at 65°C for 5 min before being transferred to ice for at least 1 min.  Each sample
had the following mixture added: 4ml RT Buffer (5x), 4ml MgCl2 (25mM), 2ml DTT (0.1M), and
1ml RNase-Out Recombinant Ribonuclease Inhibitor. The samples were mixed gently and
centrifuged briefly, followed by a 2 min incubation at 25°C.  A 1 ml volume of Super Script II
RT was added to the mix and mixed gently.  The samples were incubated at 25°C for 10min,
42°C for 50 min and then the reaction was terminated at 70°C for 15 min. Then the samples were
chilled on ice and heat them to 37°C for 20 min. The cDNA samples were stored at -20°C.
The second method of cDNA synthesis was conducted using a First Strand cDNA Synthesis Kit
from Amersham Pharmacia Biotech (Piscataway, NJ).   1 mg of each RNA sample was placed in
a sterile tube and RNAse-free H20 was added to bring the solution to a volume of 20 ml. The
RNA solution was heated to 65°C for 10 min and then chilled ice.  The Bulk First Strand cDNA
reaction mix was gently pipetted to obtain uniform suspension and then was added in 11 ml
volume to each sample.  A 1ml of DTT solution, 1 ml of primers, & the heat-denatured RNA was
added to Bulk First Strand cDNA reaction mix.  The final solution was pipetted up and down to
mix the solution and incubated at 37°C for 1 hr. The cDNA samples were stored at -20°C.
Primer sequences
Primer sequences used in this experiment for b-actin and IL-6 were acquired from Jonsdottir et.
al. (2000) see Table 1.
Primer Name Sequence Product Size Plasmid Name
b-actin sense 5¢-CCGTAAAGACCTCTATGCCA-3¢ 299 bp pCM49
b-actin antisense 5¢-AAGAAAGGGTGTAAAACGCA-3¢ 251 bp pCM53
IL-6 sense 5¢-TGGAGTTCCGTTTCTACCTG-3¢ 398 bp pCM57
IL-6 antisense 5¢-TTCATATTGCCAGTTCTTCG-3¢ 356 bp pCM61
Table 1. Primers used for Real Time PCR
Real time PCR
Real time PCR was carried out using a Smart Cycler from Cepheid (Sunnyvale, CA).  The
program used for the b-actin PCR reactions are as follows:
Stage 1: Hold; 95°C for 600 sec, optics off
Stage 2: 2-temp cycle for 35 cycles; 95°C for 15 sec, optics offSeehafer  et. al.  2001    6
                                                          60°C for 60 sec, optics on
Stage 3: Melt Curve; 60°C to 95°C, ch1 optics, 0.2°C temperature increments
The program used for the IL-6 PCR reactions are as follows:
Stage 1: Hold; 95°C for 600 secs, Optics off
Stage 2: 3-temperature cycle for 35 cycles; 95°C for 15 sec, optics off
            57°C for 15 sec, optics off
          60°C for 60 sec, optics on
Stage 3: Melt Curve; 60°C to 95°C, ch1 optics, 0.2°C temperature increments
Both sets of reactions were set up using a SYBR Green Master Mix from Applied Biosystems,
Inc (Foster, CA).  This master mix contains AmpliTaq, Mg2Cl, dNTP, and buffer.  The cDNA
and primers were added to this mix before transfer to the 25 ml Real Time PCR tubes from
Fischer Scientific (Itasca, IL).
All products were ran out on a 2% agarose gel stained with ethidium bromide.  Fluorescence
graphs and melting curves were obtained from each sample via the Smart Cycler with the aid of
Microsoft Excel.
-actin primer optimization
Samples were ran with varied concentrations of the primers and ran out with the program stated
above.  Two steps were used to optimize the primers.  1
st Step recipe is in Table 2 and 2
nd Step
recipe is in Table 3.
Samples SYBR Green For. Primer Rev. Primer cDNA H2O
A1/A2 12.5 ml 0.5 ml 0.5 ml 1 ml 10.5 ml
A3/A4 12.5 ml 0.5 ml 3 ml 1 ml 8 ml
A5/A6 12.5 ml 0.5 ml 9 ml 1 ml 2 ml
Samples SYBR Green For. Primer Rev. Primer Plasmid H2O
B1/B2 12.5 ml 3 ml 0.5 ml 1 ml 8 ml
B3/B4 12.5 ml 3 ml 3 ml 1 ml 5.5 ml
B5/B6 12.5 ml 3 ml 8.5 ml 1 ml 0 ml
Plasmid Dilution of  -actin
The recipe for B5/B6 from above was used with concentration of plasmid pCM49 taking place of
the cDNA.  The concentrations were as follows: 0.1 ng/ml, 0.01 ng/ml, and 0.001 ng/ml. Plasmids
were taken from Jonsdottir et. al. (2000)
Table 2. 1
st  Step Primer Optimization
Table 3. 2
nd Step Primer OptimizationSeehafer  et. al.  2001    7
-actin cDNA optimization
The recipe from Table 4 was used on samples to maximize the efficiency of cDNA amount to the
amount of fluorescence received.
Samples SYBR Green For. Primer Rev. Primer cDNA H2O
C1/C2 12.5 ml 3 ml 8.5 ml 1 ml 0 ml
C3/C4 12.5 ml 3 ml 8.5 ml 0.75 ml 0.25 ml
C5/C6 12.5 ml 3 ml 8.5 ml 0.5 ml 0.5 ml
C7/C8 12.5 ml 3 ml 8.5 ml 0.25 ml 0.75 ml
IL-6 primer optimization
The optimization used the same recipe for the 1
st and 2
nd step primer optimization as b-actin.
See Table 2 and 3 for recipes.
RESULTS
-actin primer optimization
The 1
st step of b-actin primer optimization samples A1-A4 did not fluoresce in the optimal
exponential curve.  A5/A6 concentrations of primers showed signs of correct curve.  See Graph 1
for 1
st primer optimization data.  The 2
nd step primer optimization increased the forward primer
amount to 3 ml instead of the 0.5 ml in 1
st step optimization. After running several data sets, the
8.5 ml concentration of the reverse primer was proved to be optimal.  The data from 2
nd step
primer optimization is shown in Graph 2.
-actin plasmid dilution
Plasmid dilutions were used to make a standard on which all samples could be compared to.  The
plasmid dilution of 0.001 ng/ml of pCM49 for b-actin showed the best the exponential curve and
was easily repeated, making it the best standard to use of the dilutions.  For plasmid dilution
curves see Graph 3.
Table 4. cDNA Optimization
Graph 2. 2
nd Step b-actin Primer Optimization Graph 1.1
st Step b-actin Primer Optimization
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-actin cDNA optimization
b-actin cDNA optimization results were exceptional.  All of the samples that were tested showed
good amplification and fluorescence.  The cDNA could be optimized further using dilution series
of the cDNA.  For this study’s purposes 0.25 ml of cDNA was chosen as the optimal amount,
because it was the lowest amount that could be accurately measured without a dilution series.
The cDNA optimization is shown on Graph 4.
IL-6 primer optimization
In this study, the IL-6 primer optimization would never give fluorescent reading, but would
amplify.  The fluorescent curves were constructed from that data are shown in Graph 5.  C6 was
an b-actin plasmid control to validate that the program was getting fluorescence and
amplification of a known sample for every run.  After the Real Time PCR reactions were
completed, the products were ran out on a 2 % agarose gel and amplification was seen.  Regular
PCR received good amplification with the IL-6 primers.  This study was not able to optimize the
IL-6 primers from Jonsdittor et. al. (2000).
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DISCUSSION
For the b-actin assay primer optimization was decided based on the set of primers that amplified
the cDNA to the point of giving over 50 fluorescent units on a fairly regular basis. The forward
primer was held constant and the reverse primer had varied concentrations to optimize the
primers.  If more primer optimization is needed varying the forward primer and holding the
reverse concentration constant could help further optimize the protocol.  While optimizing the
primers, it is suggested that one runs the PCR products out on a 2% or higher agarose gel to
check for primer dimers.  The optimal primer concentrations for this assay never showed
significant primer dimers to affect the fluorescence of the products.
The plasmid dilutions were used in such small concentrations, because when using plasmid
concentrations over 0.1 ng/ml the fluorescence graph was seen as a sin curve.  This was a
problem because it led to the conclusion at first that the reaction was not running properly or the
machine was malfunctioning.  After the plasmid concentration was dropped below 0.1 ng/ml the
desired exponential curve was seen.  From the Cycle threshold (Ct), which is where the sample
reached a fluorescent value of 30, of each plasmid dilution, a graph was constructed of the log
concentration of each verses the Ct value of that dilution as shown in Graph 6.  This graph
allowed for the sample concentration to be obtained by finding the Ct of the sample on the graph
and taking the corresponding log concentration and antilogging that value.  This was found to be
the best way to easily find the concentration of each sample.
The final step was cDNA optimization of the assay.  This process was first tried before the
plasmid dilution was ran, but this was found to be too soon to be able to optimize cDNA.  The
cDNA optimization should be the last step before running the assay, because with the plasmid
dilutions and primer optimizations being conducted first, allowed for the knowledge of what
fluorescence level can be used effectively and yet conserve cDNA optimal for this type of
protocol.  The b-actin assay was ready for implementation.
The IL-6 primer optimization was not successful.  After numerous runs on the Smart Cycler and
this study never received good fluorescent reading, the optimization was tried on a normal PCR
machine.  On that machine amplification was seen in large amounts, but every time the
optimization was tried on the Real Time PCR the samples would not reach the set Ct. After
conducting electrophoresis on the Real Time PCR products, it was discovered that the IL-6
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primers were amplifying the cDNA, but were not amplified in a dose responds manager needed
for Real Time PCR.  The next step should be to redesign IL-6 primers to amplify in a dose
response manner to allow for the use of Quantitative Real Time PCR on cDNA for IL-6.
A special thanks to Eva Wojcik and Mike Howard from USDA for the use of the Cepheid Smart
Cycler, the National Science Foundation for the funding, and the whole Reecy lab group for all
their support.Seehafer  et. al.  2001    11
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